Millennium Pharmaceuticals Limited

Allison Berger

George J Mulligan

Eric S Lightcap

Nibedita Chattopadhyay

Matthew C Schu

Erik M Koenig

Hughes Bernard

Disclosed are methods for the treatment of various solid tumors in patients in need of such treatment. The methods comprise administering to such a patient an NEDD8-activating enzyme (NAE) inhibitor such as ((1S,2S,4R)-4-(4-((1S)-2,3-dihydro-1H-inden-1-ylamino)-7H-pyrrolo[2,3-d]-pyrimidin-7-yl)-2-hydroxycyclopentyl)methyl sulfamate (MLN4924) or a pharmaceutically acceptable salt in combination with one or more chemotherapeutic agents. Also disclosed are medicaments for use in the treatment of various solid tumors.

Administration of NEDD8-activating enzyme inhibitor and chemotherapeutic agents

Disclosed are markers associated with sensitivity to treatment with proteasome inhibitors. Sensitivity is observed when RAS gene is wild type in tumor cells. Compositions and methods are further provided to assess markers of marker genes to predict outcome of treatment using proteasome inhibitors to patients having a solid tumor, such as a lung tumor or a colon tumor.

Biomarkers of response to proteasome inhibitors

Growing community of inventors

Arlington, MA, United States of America

Allison Berger